JP2011225581A5 - - Google Patents

Download PDF

Info

Publication number
JP2011225581A5
JP2011225581A5 JP2011123144A JP2011123144A JP2011225581A5 JP 2011225581 A5 JP2011225581 A5 JP 2011225581A5 JP 2011123144 A JP2011123144 A JP 2011123144A JP 2011123144 A JP2011123144 A JP 2011123144A JP 2011225581 A5 JP2011225581 A5 JP 2011225581A5
Authority
JP
Japan
Prior art keywords
cancer
therapeutic agent
prophylactic
agent according
opg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011123144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011225581A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011225581A publication Critical patent/JP2011225581A/ja
Publication of JP2011225581A5 publication Critical patent/JP2011225581A5/ja
Pending legal-status Critical Current

Links

JP2011123144A 1999-09-03 2011-06-01 癌および癌に関連する骨損失の予防または治療のための組成物および方法 Pending JP2011225581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38954599A 1999-09-03 1999-09-03
US09/389,545 1999-09-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001521333A Division JP2003508491A (ja) 1999-09-03 2000-08-18 癌および癌に関連する骨損失の予防または治療のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2011225581A JP2011225581A (ja) 2011-11-10
JP2011225581A5 true JP2011225581A5 (cg-RX-API-DMAC7.html) 2013-10-24

Family

ID=23538715

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001521333A Withdrawn JP2003508491A (ja) 1999-09-03 2000-08-18 癌および癌に関連する骨損失の予防または治療のための組成物および方法
JP2011123144A Pending JP2011225581A (ja) 1999-09-03 2011-06-01 癌および癌に関連する骨損失の予防または治療のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001521333A Withdrawn JP2003508491A (ja) 1999-09-03 2000-08-18 癌および癌に関連する骨損失の予防または治療のための組成物および方法

Country Status (14)

Country Link
US (1) US20060019887A1 (cg-RX-API-DMAC7.html)
EP (2) EP1140136B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003508491A (cg-RX-API-DMAC7.html)
KR (1) KR20010085996A (cg-RX-API-DMAC7.html)
CN (1) CN1345246A (cg-RX-API-DMAC7.html)
AT (1) ATE362374T1 (cg-RX-API-DMAC7.html)
AU (1) AU6788900A (cg-RX-API-DMAC7.html)
CA (1) CA2349406C (cg-RX-API-DMAC7.html)
DE (1) DE60034871T2 (cg-RX-API-DMAC7.html)
ES (1) ES2287028T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0104688A3 (cg-RX-API-DMAC7.html)
IL (1) IL142900A0 (cg-RX-API-DMAC7.html)
WO (1) WO2001017543A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200103565B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja) 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
WO2000024416A1 (en) * 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
MXPA03011270A (es) * 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU2003240754B2 (en) * 2002-04-10 2009-02-26 Merck Serono Sa Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US20050287603A1 (en) * 2002-06-07 2005-12-29 Gorczynski Reginald M Modulation of bone development
CA2587209A1 (en) 2004-12-13 2006-06-22 Evogenix Ltd Osteoprotegerin variant proteins
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
CN102242209B (zh) * 2011-07-05 2013-12-11 北京大学人民医院 基于多个基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
WO2013147899A1 (en) * 2012-03-31 2013-10-03 R-PHARM, CJSC (Closed Joint Stock Company) Osteoprotegerin derived composition and use thereof
KR20160127824A (ko) * 2014-03-06 2016-11-04 알-팜 오버씨즈, 인코포레이티드 오스테오프로테게린 유래의 rankl 억제제
KR101576904B1 (ko) * 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
WO2018082758A1 (en) * 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
CN110483647B (zh) * 2019-08-19 2021-02-09 重庆大学附属肿瘤医院 一种抗肿瘤多肽及其应用
BR112022020809A2 (pt) * 2020-04-15 2023-02-23 Theradaptive Inc Composições e métodos para entrega terapêutica direcionada ao osso
CA3197104A1 (en) * 2020-11-11 2022-05-19 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
FR2640537B1 (fr) * 1988-12-21 1992-02-21 Levy Guy Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin

Similar Documents

Publication Publication Date Title
CA2349406A1 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ES2633453T3 (es) Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
WO2022234852A1 (ja) 環状ペプチド化合物の医薬用途
AU2003218600C1 (en) ERBB3 based methods and compositions for treating neoplasms
JP2010518006A5 (cg-RX-API-DMAC7.html)
JP2010529026A5 (cg-RX-API-DMAC7.html)
CA2726917A1 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2012500001A5 (cg-RX-API-DMAC7.html)
EA025182B1 (ru) Композиция, включающая афлиберцепт, фолиновую кислоту, 5-фторурацил (5-fu) и ириноцетан (folfiri), для лечения колоректального рака
JP7374765B2 (ja) 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用
ES2897782T3 (es) Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
AU2017225015B2 (en) Medical Use
MX2013015333A (es) Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos.
CN104017049B (zh) 一种肿瘤特异性靶向多肽及其应用
CN100422211C (zh) 抑制igf-i和-ii的gh-rh拮抗性相似物
EP1653992A1 (en) Use of a vegf antagonist in combination with radiation therapy
US20050196340A1 (en) Use of a VEGF antagonist in combination with radiation therapy
JP2021516222A (ja) 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法
Xu et al. New agonist-and antagonist-based treatment approaches for advanced prostate cancer
CN116406274B (zh) 用于治疗冠状病毒的cd3抗体
JP2021523096A5 (cg-RX-API-DMAC7.html)
KR20080056714A (ko) ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
CN120860242A (zh) 抗her2抗体药物偶联物治疗her2阴性的乳腺癌的用途
JP2021523931A5 (cg-RX-API-DMAC7.html)
Choppin et al. A novel anti-PTH1R receptor antagonist monoclonal antibody reverses hypercalcemia induced by PTH or PTHrP: a potential treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy